Celltrion and Celltrion Healthcare are set to launch an integrated corporation. The market capitalization of the integrated Celltrion is expected to reach around 40 trillion won.

The launch of the integrated Celltrion is anticipated to unify the previously dispersed biosimilar production and distribution processes. This merger may address longstanding controversies such as allegations of unfair business partnership and inflation of sales figures.

The newly merged entity aims to expand its business focus from primarily biosimilars to a new drug development. Seo Jung-jin, the chairman of Celltrion, announced company’s initiative to increase the sales to 12 trillion won by 2030 thr